Mohammed Majrashi
Overview
Explore the profile of Mohammed Majrashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mobarki M, Alhakami N, Ahmad M, Mommtaz Ghannam W, Mosaad N, Hakami S, et al.
Cureus
. 2025 Jan;
16(12):e75318.
PMID: 39776696
Basidiobolomycosis is a rare fungal infection that is triggered by the environmental saprophyte . Basidiobolomycosis usually presents as an infection beneath the skin and seldom impacts the digestive system. There...
2.
Desai D, Majrashi M, Pathak S, Almaghrabi M, Liu K, Pondugula S, et al.
Cancer Rep (Hoboken)
. 2024 Apr;
7(4):e2074.
PMID: 38627904
Background: Iatrogenesis is an inevitable global threat to healthcare that drastically increases morbidity and mortality. Cancer is a fatal pathological condition that affects people of different ages, sexes, and races...
3.
Sindi A, Hosny K, Rizg W, Sabei F, Madkhali O, Bakkari M, et al.
Drug Deliv
. 2023 Feb;
30(1):2184311.
PMID: 36846914
Numerous problems affect oral health, and intensive research is focused on essential oil-based nanoemulsions that might treat prevent or these problems. Nanoemulsions are delivery systems that enhance the distribution and...
4.
Sindi A, Rizg W, Khan M, Alkhalidi H, Alharbi W, Sabei F, et al.
Drug Deliv
. 2023 Jan;
30(1):2173337.
PMID: 36708105
The use of essential oil-based nanoemulsions (NEs) has been the subject of extensive research on a variety of conditions affecting the oral cavity. NEs are delivery methods that improve the...
5.
Abdulaal W, Hosny K, Alhakamy N, Bakhaidar R, Almuhanna Y, Sabei F, et al.
Drug Deliv
. 2023 Jan;
30(1):2164094.
PMID: 36588399
Low bone mass, degeneration of bone tissue, and disruption of bone microarchitecture are all symptoms of the disease osteoporosis, which can decrease bone strength and increase the risk of fractures....
6.
Ajaz N, Abbas A, Afshan R, Irfan M, Khalid S, Asghar S, et al.
Pharmaceuticals (Basel)
. 2022 Nov;
15(11).
PMID: 36422529
In this paper, we fabricated semi-interpenetrating polymeric network (semi-IPN) of hydroxypropyl-β-cyclodextrin--poly(acrylic acid)/poly(vinyl pyrrolidone) (HP-β-CD-g-poly(AA)/PVP) by the free radical polymerization technique, intended for colon specific release of dexamethasone sodium phosphate (DSP)....
7.
Jiffrin R, Razak S, Jamaludin M, Amir Hamzah A, Mazian M, Jaya M, et al.
Polymers (Basel)
. 2022 Sep;
14(18).
PMID: 36145871
A medication's approximate release profile should be sustained in order to generate the desired therapeutic effect. The drug's release site, duration, and rate must all be adjusted to the drug's...
8.
Almikhlafi M, Karami M, Jana A, Alqurashi T, Majrashi M, Alghamdi B, et al.
Curr Neuropharmacol
. 2022 Aug;
21(5):1165-1183.
PMID: 36043795
Abnormal mitochondrial morphology and metabolic dysfunction have been observed in many neurodegenerative disorders (NDDs). Mitochondrial dysfunction can be caused by aberrant mitochondrial DNA, mutant nuclear proteins that interact with mitochondria...
9.
Pondugula S, Salamat J, Abbott K, Flannery P, Majrashi M, Almaghrabi M, et al.
Liver Res
. 2021 Dec;
5(4):239-242.
PMID: 34900377
Background And Aim: Chronic exposure to chemotherapeutics can lead to severe adverse events including hepatotoxicity. A combination chemotherapy regimen of doxorubicin (DOX) and cyclophosphamide (CPS) is employed in treatment of...
10.
Pondugula S, Harshan A, Ramesh S, Govindarajulu M, Almaghrabi M, Majrashi M, et al.
Cardiovasc Toxicol
. 2021 Oct;
22(1):67-77.
PMID: 34623620
Administration of Chemotherapeutics, especially doxorubicin (DOX) and cyclophosphamide (CPS), is commonly associated with adverse effects such as myelosuppression and cardiotoxicity. At this time, few approved therapeutic options are currently available...